(Q34661011)

English

Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

0 references

1 reference

Europe PubMed Central

Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

0 references

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

Christoph Correll

3

object named as

Christoph U Correll

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Lawrence Maayan

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Julia Vakhrusheva

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

24 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Neuropsychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1520-1530

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Pharmacological management of atypical antipsychotic-induced weight gain.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Compelling or irrelevant? Using number needed to treat can help decide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Balancing efficacy and safety in treatment with antipsychotics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Interventions to reduce weight gain in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Interventions to reduce weight gain in schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Challenges in the management of bipolar depression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Nizatidine for the treatment of patients with quetiapine-induced weight gain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Predictors of noncompliance in patients with schizophrenia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Metformin-associated lactic acidosis: case reports and literature review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

7 July 2018

The impact of weight gain on quality of life among persons with schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

Amantadine for weight gain associated with olanzapine treatment

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

26 October 2018

Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

26 October 2018

A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

26 October 2018

Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

26 October 2018

Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055458

26 October 2018

A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin Treatment of Weight Gain Associated With Initiation of Atypical Antipsychotic Therapy in Children and Adolescents

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.21

21 January 2018

FAILURE OF DEXTROAMPHETAMINE SULFATE TO INFLUENCE EATING AND SLEEPING PATTERNS IN OBESE SCHIZOPHRENIC PATIENTS: CLINICAL AND PHARMACOLOGICAL SIGNIFICANCE

1 reference

https://pubmed.ncbi.nlm.nih.gov/20336059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacogenetics of antipsychotic-induced weight gain

1 reference

https://pubmed.ncbi.nlm.nih.gov/20336059

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/NPP.2010.21

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34661011&oldid=2196924094"